In KRAS-mutant lung adenocarcinomas, significant activation of NRF1 targets was associated with worse prognosis (Figure S24E), consistent with NRF1’s role as a regulator of the proteasome pathway,48 a key dependency in KRAS-mutant cancers.49 The gene discussed is NRF1; the disease is cancer.